Deerfield Management Company L.P. Series C Buys 120,991 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Deerfield Management Company L.P. Series C grew its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 4.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,938,754 shares of the company's stock after purchasing an additional 120,991 shares during the period. Deerfield Management Company L.P. Series C owned approximately 4.35% of Perspective Therapeutics worth $9,375,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in CATX. Corton Capital Inc. purchased a new position in shares of Perspective Therapeutics in the fourth quarter valued at about $61,000. Cubist Systematic Strategies LLC bought a new stake in Perspective Therapeutics in the fourth quarter worth $834,000. Balyasny Asset Management L.P. bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $418,000. BNP Paribas Financial Markets boosted its position in shares of Perspective Therapeutics by 7.4% during the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company's stock valued at $163,000 after buying an additional 3,529 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth approximately $51,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Trading Up 0.4%

CATX traded up $0.01 on Tuesday, hitting $2.52. The company had a trading volume of 555,747 shares, compared to its average volume of 786,761. The business's fifty day simple moving average is $2.26 and its 200 day simple moving average is $3.85. Perspective Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $19.05.

Insider Activity at Perspective Therapeutics

In related news, Director Robert F. Williamson III bought 22,192 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the acquisition, the director now owns 70,837 shares in the company, valued at $160,799.99. This trade represents a 45.62% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Johan M. Spoor bought 22,026 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the acquisition, the chief executive officer now directly owns 59,383 shares in the company, valued at approximately $133,017.92. This represents a 58.96% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 115,696 shares of company stock valued at $256,344 in the last three months. 3.72% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CATX. Royal Bank of Canada cut their target price on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a research report on Thursday, March 27th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research note on Monday, March 31st. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $12.75.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.